Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Henning Gall (Giessen, Germany), Henning Gall, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Ekkehard Grünig, Michael Halank, Hans Klose, Jean-Luc Vachiéry, Hubert Wirtz, Tobias Lange, Repke J. Snijder, Silvia Ulrich, Ralf Ewert, Iraklis Tsangaris, Joanna Pepke-Zaba, Irene Lang, Judith Löffler-Ragg, Vincent Cottin, Anco Boonstra, Sean Gaine, Paul A. Corris, Andrew Peacock, Gérald Simonneau, Miguel-Angel Gómez Sánchez, Jens Klotsche, David Pittrow, Christian Meier, Monika Brunn, Marc Humbert. Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry. Eur Respir J 2016; 48: Suppl. 60, 2408

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre Source: Eur Respir J 2012; 39: 945-955 Year: 2012 Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Global fibrinolytic profile in patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 Intravenous prostacyclin for pulmonary hypertension: Patient’s perspective on complications Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Disease-targeted treatment improves cognitive function in patients with pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Epoprostenol dosing by concomitant therapies in the PROSPECT registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015